אטופיקה 100 מגמל תמיסה למתן דרך הפה לחתולים וכלבים וטרינרי
euromar ltd - ciclosporin - תמיסה (פומי) - ciclosporin 100 mg / 1 ml
אטופיקה 25 מג לכלבים וטרינרי
euromar ltd - ciclosporin - קפסולות ג'לטין רכות - ciclosporin 25 mg
אטופיקה 50 מג לכלבים וטרינרי
euromar ltd - ciclosporin - קפסולות ג'לטין רכות - ciclosporin 50 mg
אנפלייט 250 מקג
amgen europe b.v. - romiplostim - אבקה להכנת תמיסה לזריקה - romiplostim 250 mcg/vial - romiplostim - romiplostim - nplate is indicated for the treatment of thrombocytopaenia in adult patients with chronic immune (idiopathic) thrombocytopaenic purpura (itp)- who are non-splenectomised and have had an inadequate response, or are intolerant, to both corticosteroids and immunoglobulins;-who are splenectomised and have had an inadequate response to splenectomy
מימפרה 30 מ"ג
amgen europe b.v. - cinacalcet hydrochloride 30 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
מימפרה 60 מ"ג
amgen europe b.v. - cinacalcet hydrochloride 60 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
מימפרה 90 מ"ג
amgen europe b.v. - cinacalcet hydrochloride 90 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
ניופוגן 30 mu בקבוקונים
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 48 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 30 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).